Sodium Oxybate: Medication Class and Side Effects
Sodium oxybate is a central nervous system (CNS) depressant and Schedule III controlled substance that is the sodium salt of gamma-hydroxybutyrate (GHB), used primarily to treat narcolepsy with cataplexy and excessive daytime sleepiness. 1, 2
Medication Classification
Sodium oxybate functions as a CNS depressant with the following critical regulatory characteristics:
- FDA Schedule III controlled substance (the active moiety GHB itself is Schedule I)
- Carries an FDA black box warning for CNS depression and respiratory depression risk
- Available only through a Risk Evaluation and Mitigation Strategy (REMS) program using certified pharmacies 1, 2
The mechanism involves increasing serotonin turnover, interacting with opioid systems, and potentially acting as a GABA-B receptor agonist, though the exact mode of action remains uncertain 3.
Side Effects Profile
Common Adverse Events (≥5% incidence)
In adults with narcolepsy or idiopathic hypersomnia 2:
- Nausea (most common, 18% in trials)
- Headache
- Dizziness (15%)
- Anxiety
- Insomnia
- Decreased appetite
- Hyperhidrosis (excessive sweating)
- Vomiting
- Diarrhea
- Dry mouth
- Parasomnia
- Somnolence
- Fatigue
- Tremor
- Nocturnal enuresis (bedwetting, 7%)
- Chest discomfort
- Sleep disturbances
- Confusion (3%)
- Nausea
- Enuresis (bedwetting)
- Vomiting
- Headache
- Weight decreased
- Decreased appetite
- Dizziness
- Sleepwalking
Serious Adverse Events
Critical safety concerns requiring immediate attention 1, 2:
- Respiratory depression (particularly with CNS depressant co-administration or alcohol)
- Sleep-disordered breathing/central sleep apnea (documented by polysomnography in pediatric trials)
- Depression and suicidality (monitor for emergent or worsening symptoms)
- Neuropsychiatric reactions: acute psychosis, confusion, severe anxiety
- Altered consciousness and coma (especially with overdose or misuse)
- Seizures (associated with abuse/misuse)
- Death (when combined with alcohol or other CNS depressants)
Age-Related Considerations
Elderly patients (≥65 years) experience 2:
- Higher discontinuation rates (21% vs 19% in younger adults)
- Markedly increased headache frequency (39% vs 19%)
- Psychosis risk increases with age and typically occurs early after drug initiation 4
Pediatric-specific concerns 1:
- Central sleep apnea documented on polysomnography
- Depression and suicidal ideation
- Parasomnias including sleepwalking
Critical Safety Warnings
Absolute Contraindications 2:
- Combination with sedative hypnotics or alcohol (life-threatening CNS depression)
- Succinic semialdehyde dehydrogenase deficiency
Special Populations 2:
Pregnancy:
- May cause fetal harm based on animal data
- Rapid placental transfer documented
- Newborns may be very sleepy with decreased Apgar scores
- Human data insufficient to determine risk
Hepatic impairment:
- Start at half the usual dose due to increased drug exposure 2
Clinical Context
Despite moderate-quality evidence supporting its efficacy for excessive daytime sleepiness, cataplexy, and disease severity 1, sodium oxybate carries significant risks. In clinical practice, approximately 60% of patients experience at least one side effect, and 26.6% discontinue treatment due to limiting adverse events 4. However, the American Academy of Sleep Medicine provides a STRONG recommendation for its use in adults with narcolepsy, as benefits outweigh risks when properly monitored 1.
The most concerning aspect is the abuse potential and risk of chemical submission (date rape drug), facilitated by its odorless, colorless nature 5. This necessitates the REMS program and careful patient selection.
Older patients are particularly vulnerable to serious psychiatric side effects (especially psychosis), which typically manifest early in treatment 4. Clinicians must maintain heightened vigilance during the first weeks of therapy, particularly in patients over 65 years of age.